Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CollaGenex (CGPI) FDA PENDING -- Ignore unavailable to you. Want to Upgrade?

To: Clouseau who wrote (58)	10/27/1999 2:22:00 PM
From: biowa	Read Replies (1) \| Respond to of 142

Dave, I don't believe that Periostat has the ADA seal. For what its worth, it doesn't seem to have hurt Periostat sales growth: NEWTOWN, Pa.--(BUSINESS WIRE)--Oct. 25, 1999--CollaGenex Pharmaceuticals, Inc. (Nasdaq:CGPI) announced total net revenues of $4.3 million in the third quarter of 1999 compared to $401,000 in net revenues in the third quarter of 1998. Net sales of Periostat(R), the Company's lead drug for the treatment of adult periodontitis, were $4.2 million for the third quarter of 1999, whichrepresented a 31% increase over Periostat net sales in the second quarter of 1999. go2net.newsalert.com biowa

To: Clouseau who wrote (58)	10/28/1999 11:41:00 AM
From: biowa	Respond to of 142

Dave, ATRX bad new is right. Absolutely flat-line sales growth in Atridox; I love how they tried to couch it as some phenomenal growth over 3Q98 - WHEN THE PRODUCT WASN'T EVEN FULLY LAUNCHED!! That would tick me off right there... That is worthy of some kinda IR back handspring award. <g> BTW, I'm not short ATRX (even though it may sound that way) nor do I think they pose a particularly strong threat to CGPI. I just couldn't let that PR pass "un-saluted." biowa